About

About 33X

33X is a UK early-stage research platform built around traceable evidence, consistent scoring, and clear financial analysis.

Browse coverageRead methodology

Research Platform

Structured output, evidence-first claims, and consistent analytical standards. Think of it as a research desk, built into a product.

Why 33X Exists

Early-stage deals move quickly, but diligence often depends on scattered notes, weak source trails, and inconsistent scoring. 33X turns that process into a repeatable analysis workflow.

We deliver structured deal, market, company, and financial analysis for paid members: clear claims, source-linked context, and scoring that stays consistent across the pipeline.

What We Solve

  • Pipeline noise: weekly curation reduces low-signal opportunities before deep review.
  • Evidence gaps: core claims are tied to source material and confidence context.
  • Scoring drift: stage-aware models keep comparisons fair from pre-seed to scaling.
  • Output inconsistency: modular, structured output keeps analysis stable and comparable.

At A Glance

  • •Member-funded coverage focused on UK early-stage companies and raises.
  • •Traceable evidence and clear confidence context on key claims.
  • •Weekly curation so members can triage quickly without losing research depth.
  • •Stage-aware scores converted into one transparent decision view.

Approach

  1. 01Ingest opportunities and source material.
  2. 02Verify core claims and flag uncertainty.
  3. 03Generate structured modules and factor scores.
  4. 04Release a clean, comparable analysis view.

Delivery Model

Coverage is staged, versioned, and built for repeat research and decision cycles.

Curated Research Pipeline

We continuously ingest opportunities from founders, investor networks, and partner channels. Each company is triaged with standard filters before it reaches analyst review.

The output is a focused weekly pipeline where members review evidence-linked companies, not raw inbound volume.

Stage-Aware Scoring

We do not force one valuation logic onto every company. 33X adapts the model to stage, then normalizes outcomes for comparability.

  • Pre-seed: team quality, product readiness, and market intent.
  • Seed: traction and execution benchmarks with scorecard-style weighting.
  • Post-seed: market-comparable framing to calibrate valuation expectations.

Editorial Standards

How independence and rigour are maintained across the pipeline.

33X is built by practitioners with backgrounds across high-growth operating roles and early-stage investment analysis. The platform exists because consistent, evidence-linked analysis was absent from the UK angel market — not to replace judgement, but to give it a better foundation.

We operate with no commercial relationship to the companies we cover. Coverage decisions are editorial, not commercial. Every claim is tied to source material; confidence is always explicit.

Our output is a structured research layer — not a shortlist, not a recommendation. We score for survivability and analytical consistency. What you do with that is yours.

About | 33X